thymosin α-1 vs thymalin

thymosin α-1 (B-tier) vs thymalin (D-tier). mechanism, trials, evidence boundaries, dosing literature. side-by-side reference.

thymosin α-1 · tier B

thymic immune peptide. approved abroad for hepatitis B. used stateside for generic 'immune support.'

thymic immune peptide. approved abroad for chronic hepatitis B adjunct. used stateside for off-label 'immune support' on much thinner data.

global Zadaxin · 35 markets · half-life approximately 2 hours in plasma (subcutaneous); dosing regimens typically twice weekly in approved indications · healing

thymalin · tier D

a drug made from calf thymus glands, sold for immune support and to slow ageing. registered in the ussr in 1982 and never once entered into a trial registry. the largest human dataset belongs to the two men who made it.

a mixture of peptides extracted from calf thymus glands, registered as a medicine in the ussr in 1982 and sold for immune support and anti-ageing. it moves immune numbers: every group that has put it beside a control and counted t cells has watched them go up from baseline. the anti-ageing claim rests on one dataset of 266 older people, reported by the two men who developed the compound, published twice from that single cohort and unchecked by anyone else since. 44 years of published clinical reporting, and zero registered trials in any registry.

0 registered trials · 44 yrs · half-life not characterised in any species. no pharmacokinetic study appears in the 293 PubMed records · healing

at a glance

• thymosin α-1: tier B · global Zadaxin · 35 markets
• thymalin: tier D · 0 registered trials · 44 yrs

reptides grades the research record and cites the literature behind every call. research reference only; not medical advice.